share_log

Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy

Johnson & Johnson Says Intra-Cellular Acquisition Includes CAPLYTA (Lumateperone), The First And Only US FDA-Approved Treatment For Bipolar I And II Depression As An Adjunctive And Monotherapy

強生表示,細胞內收購包括CAPLYTA(盧美他匹),這是美國FDA批准的首個也是唯一一個可用於雙相I型和II型抑鬱症的輔助治療和單藥治療的藥物。
Benzinga ·  01/13 11:35

Johnson & Johnson expects to fund the transaction through a combination of cash on hand and debt. Johnson & Johnson expects to maintain a strong balance sheet and to continue to support its stated capital allocation priorities of R&D investment, competitive dividends, value-creating acquisitions, and strategic share repurchases.

強生預計將通過手頭現金和債務的組合來資助該交易。強生預計將保持強勁的資產負債表,並繼續支持其聲明的資本分配優先事項,包括研發投資、具有競爭力的分紅派息、創造價值的收購以及戰略性的股票回購。

Johnson & Johnson will provide commentary on any potential impact to Adjusted Earnings Per Share (EPS) from the transaction when it provides its initial full year 2025 guidance during the fourth quarter earnings call on Wednesday, January 22, 2025.

強生將在2025年1月22日星期三的第四季度業績發佈會上提供關於該交易對調整後每股收益(每股收益)潛在影響的評論,以及在此時提供其初步的2025年全年指引。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。